NLRP3 and neoplasm: The results would provide a novel anti-cancer strategy using NLRP3 inflammasome inhibitors, such as celastrol to modulate the myeloid cells in tumor microenvironment and tumor metastatic potential by reducing the IL-1β level at tumor sites.